Share on StockTwits

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings results on Monday. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.24, American Banking & Market News reports. The company had revenue of $29.67 million for the quarter, compared to the consensus estimate of $19.85 million.

On a related note, analysts at Jefferies Group reiterated a “hold” rating on shares of Supernus Pharmaceuticals in a research note on Thursday, May 15th. They now have a $9.00 price target on the stock.

Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded down 1.77% on Monday, hitting $8.33. The stock had a trading volume of 484,736 shares. Supernus Pharmaceuticals has a one year low of $5.84 and a one year high of $11.47. The stock has a 50-day moving average of $9.77 and a 200-day moving average of $9.22. The company’s market cap is $350.2 million.

Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.